Sotatercept Study for Pulmonary Arterial Hypertension in India
Treatments studied
Part of Lungs & breathing clinical trials.
This study tests a new drug called sotatercept to help people with pulmonary arterial hypertension (PAH)—a condition where blood vessels in the lungs become too narrow, making the heart work harder. The drug may help improve how well your lungs and heart work together.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with PAH (Group 1 pulmonary hypertension) confirmed by a heart catheterization procedure at least 1 year ago
- You are currently taking stable doses of PAH medications and diuretics (water pills), which you've been on without recent changes
- Your PAH symptoms are classified as WHO Functional Class II or III (mild to moderate shortness of breath with activity)
- You do not have other types of pulmonary hypertension (Groups 2, 3, 4, or 5)
- You do not have uncontrolled high blood pressure, untreated sleep apnea, liver disease, or certain heart valve problems
- You do not have active cancer requiring treatment in the past 5 years
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a medicine called sotatercept to see if it can improve how the right side of your heart pumps in people with PAH. It may help you feel better and slow down the disease.
This Phase 2 trial tests sotatercept, a medicine that targets the blood-vessel changes in pulmonary arterial hypertension (PAH), in children. It may help improve how well the heart and lungs work by changing the underlying disease process.
This study tests a new medicine called sotatercept in Japanese children who have pulmonary arterial hypertension (PAH)—a condition where blood vessels in the lungs become narrow and stiff, making it harder for the heart to pump blood through them. The medicine may help improve how well their hearts and lungs work together.
This study is for people who have already taken part in a clinical trial of sotatercept for pulmonary arterial hypertension and done well enough to continue. It tests the long-term safety and effectiveness of staying on sotatercept, an investigational treatment that helps lower blood pressure in the lungs.
This trial is for adults with pulmonary arterial hypertension (PAH) who have been taking sotatercept for at least 6 months and have stable, low-risk disease. The study will check if it's safe to stop one of their other PAH treatments (a prostacyclin or selexipag).
This study tests a new medicine called IKT-001 for people with pulmonary arterial hypertension (PAH). It aims to see if IKT-001 helps improve exercise ability and other symptoms when added to current PAH therapies.
Hear when a new Pulmonary Arterial Hypertension trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.